Dr. Fremeau is a molecular neuroscientist and biotech entrepreneur with a track record of scientific innovation and program leadership at the intersection of target validation, translation, and clinical development. As the Founder and CSO of BrainStorm Therapeutics, he is developing an AI-powered human brain organoid platform to discover therapeutic candidates that halt, prevent, or reverse synaptic network dysfunction and neurodegeneration. In his prior position as CSO at Vyant Bio, Dr. Fremeau spearheaded the company's transition from a services and manufacturing-focused entity to a drug discovery platform company. Under his leadership, Vyant Bio developed a promising therapeutic pipeline targeting genetic neurodevelopmental disorders, including Rett syndrome and CDKL5 deficiency disorder. Through phenotypic screening of Rett patient-derived cortical organoids, the team identified clinical candidates for Rett syndrome with a differentiated mechanism of action, advancing to a Phase 2 clinical trial funded by a Clinical Trial Award from the Department of Defense. Prior to moving to biopharma, Dr. Fremeau led a productive academic career at the University of California San Francisco and Duke University Medical School. He made seminal contributions to the first molecular and functional characterization of the receptors and transporters for the biogenic amine and amino acid neurotransmitters.